EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, uniQure NV's Enterprise Value is $-180.21 Mil.
uniQure NV's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-135.36 Mil. Therefore, uniQure NV's EV-to-FCF for today is 1.33.
The historical rank and industry rank for uniQure NV's EV-to-FCF or its related term are showing as below:
QURE'
s EV-to-FCF Range Over the Past 10 Years
Min: -436.94 Med: -5.08 Max: 46.38
Current: 1.33
During the past 13 years, the highest EV-to-FCF of uniQure NV was 46.38. The lowest was -436.94. And the median was -5.08.
QURE's EV-to-FCF is ranked better than 60.85% of 378
companies
in the Biotechnology industry
Industry Median: 7.545
vs QURE: 1.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-15), uniQure NV's stock price is $5.06.
uniQure NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.210. Therefore, uniQure NV's PE Ratio for today is At Loss.
uniQure NV EV-to-FCF Historical Data
The historical data trend for uniQure NV's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, uniQure NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where uniQure NV's EV-to-FCF falls into.
uniQure NV EV-to-FCF Calculation
uniQure NV's EV-to-FCF for today is calculated as:
uniQure NV's current Enterprise Value is $-180.21 Mil.
uniQure NV's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-135.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (NAS:QURE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
uniQure NV's share price for today is $5.06.
uniQure NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
uniQure NV EV-to-FCF Related Terms
Thank you for viewing the detailed overview of uniQure NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QURE has been successfully added to your 